Why Teva's Stock Could Crash Another 50% Post author:Sam Post published:November 7, 2017 Post category:BioPharma Teva continues to be battered by its massive debt load and struggling pipeline. Source: BioSpace You Might Also Like Bayer's Former Head of Discovery Lands New CSO Gig at Shire November 30, 2017 Editas CEO to Testify at a U.S. Senate Hearing Next Week November 7, 2017 Massachusetts??? Homology Medicines Snags $83.5M to Advance AMEnDR into Human Trials July 31, 2017
